Hearings

Fentanyl Analogues: Perspectives on Classwide Scheduling

Subcommittee on Crime, Terrorism, and Homeland Security

Location: 2141 RHOB

Fentanyl Analogues: Perspectives on Classwide Scheduling


Hearing: Fentanyl Analogues: Perspectives on Classwide Scheduling

Subcommittee on Crime, Terrorism, and Homeland Security (Committee on the Judiciary)

Tuesday, January 28, 2020 (10:00 AM)

2141 RHOB
Washington, D.C. 20515-515

Support Documents

  • Notice of Hearing [PDF]
  • Witness List [PDF] Added 01/27/2020 at 01:52 PM
  • Member Attendance [PDF] Added 01/28/2020 at 03:42 PM
  • Mr. Doug Collins [PDF] Added 01/30/2020 at 10:17 AM

First Published: January 17, 2020 at 05:15 PM

Witnesses

Mr. Kevin L. Butler Esq.
Federal Public Defender, Northern District of Alabama

  • Witness Statement [PDF]
  • Truth in Testimony [PDF]
  • Witness Biography [PDF]

Dr. Daniel Ciccarone Professor
Professor of Family and community Medicine, University of California, San Francisco, CA

  • Witness Statement [PDF]
  • Truth in Testimony [PDF]
  • Witness Biography [PDF]

Dr. Sandra D. Comer
Professor of Neurobiology, Department of Psychiatry, Columbia University

  • Witness Statement [PDF]
  • Truth in Testimony [PDF]
  • Witness Biography [PDF]

Dr. Brett P Giroir
Assistant Secretary for Health, Department of Health and Human Services, Washington, DC

  • Witness Statement [PDF]
  • Witness Truth in Testimony [PDF]
  • Witness Biography [PDF]

Mr. Donald A. Holman
Arlington, VA

  • Witness Statement [PDF]
  • Truth in Testimony [PDF]
  • Witness Bio [PDF]

Ms. Amanda Liskamm Esq.
Director of Opioid Enforcement and Prevention Efforts, U.S. Department of Justice, Washington, DC

  • Witness Statement [PDF]
  • Truth in Testimony [PDF]
  • Witness Biography [PDF]